Generex Announces Agreement with the Immune Tolerance Network
The proprietary technology being developed at Antigen Express allows for more potent and specific activation of immune cells (CD4+ T helper cells), both after immunization and using blood cells ex vivo. In Type I Diabetes, these cells become aberrantly activated to recognize proteins associated with cells involved in insulin secretion, which ultimately leads to the destruction of these cells. Antigen Express technology allows for the more sensitive detection of these inappropriately activated cells in the blood.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.